Matthew Rabinowitz, PhD
Chief Executive Officer
Dr. Matthew Rabinowitz has had dual careers in industry and academia. He completed his B.A., M.Sc. and Ph.D. degrees at Stanford University, receiving both the Levin and Terman Awards — the highest academic honors offered respectively in engineering and physics — and a graduate fellowship to the school of engineering. While completing his dissertation, Dr. Rabinowitz co-founded an intelligent online merchandizing company, Panop.com, which later sold for $100M. Shortly after, Dr. Rabinowitz started his second company, Rosum, which developed a location technology using TV signals to augment GPS. Rosum received the World Economic Forum “100 Technology Pioneers” award when he was CTO.
In 2003, Dr. Rabinowitz’s life took a turn. A family member had a child born with a genetic disease and the child died. Dr. Rabinowitz experienced firsthand the trauma, stress, and devastation that an unexpected diagnosis of genetic disease can bring to a family and he was moved to action.
Drawing on expertise from his seemingly unrelated background, Dr. Rabinowitz embarked on a journey with the goal of ensuring that other families need not experience similar pain wrought by the inability to have a healthy child. Bringing together a team of experts in medicine, engineering, statistics, and genetics, along with his own skills in optimization, signal processing, informatics, and entrepreneurship – Natera was born.
Dr. Rabinowitz is now an authority in the field of prenatal and preconception informatics-based genetic testing. He has served as the Principal Investigator on six research grants awarded by the National Institutes of Health from which multiple publications have emerged in the leading journals of the field such as Bioinformatics, Human Reproduction, and Molecular Human Reproduction. He actively presents at medical conferences around the world, including at the annual meeting of the American College of Medical Genetics, American Society of Reproductive Medicine, and Fetal Medicine Foundation World Congress.
Dr Rabinowitz is a board member, advisor, and angel investor for multiple technology companies in the fields of biotech, communications, cleantech and healthcare. He has received the Scott Helt Memorial Award from IEEE and was selected by MIT Technology Review Magazine as one of the top 35 technology innovators under 35 in the US.
Natera’s results have been no less than remarkable. Dr. Rabinowitz and the entire Natera team share a dedicated passion to bringing the breakthrough Parental Support technology to those who need it most in their pursuit of a healthy family.
Jonathan Sheena, M.Eng
Chief Technology Officer
Mr. Sheena is company co-founder and an experienced entrepreneur with proven success in technology innovation. Before co-founding Natera, Mr. Sheena co-founded PocketThis with offices in the UK and the US and sold cutting edge server technology to mobile networks worldwide. Mr. Sheena’s background is in personalization technology. While a graduate student at MIT, and in partnership with the Associated Press, Reuters, Knight Ridder, ABC, and the New York Times, he helped architect the first web-based personalized newspaper called “Fishwrap”. The technology was licensed by and deployed to newspapers worldwide, most notably the San Francisco Chronicle. After MIT, Mr. Sheena worked as a software architect at Firefly, a pioneering company in online community, personalization and collaborative filtering. Firefly was purchased by Microsoft, where Mr. Sheena then worked to bring online the largest running personalization and online identity system used by tens of millions of people around the globe. He holds both M.Eng. and S.B. degrees from MIT as well as a number of patents in internet and mobile technology.
Matthew Hill, PhD
Vice President, Research & Development
Dr. Hill’s expertise is in the areas of genetics, molecular biology, and bioinformatics. He received is B.S. in Biology from Cornell University and a Ph.D. in Genetics from Stanford University. While at Stanford Dr. Hill constructed the first genetic map of an important chordate model organism that led to important insights about the nature of genome evolution. In the process he also developed an algorithm that reduced the compute time required for whole genome sequence alignments from weeks to hours. His prior industry experience involved developing techniques for interrogating the function of genes. Since joining Natera in early 2009 he has been instrumental in leading the research and development of single-gene PGD, translocation testing, carrier screening, non-invasive paternity testing, and non-invasive prenatal testing.
Styrmir Sigurjonsson, PhD
Senior Director, Statistics
Dr. Sigurjonsson's expertise is in the areas of probabilistic modeling and statistics. Prior to Natera, Dr. Sigurjonsson held various positions in the financial services sector. He developed probability of default models in fixed income at Citi's investment bank. He later joined Straumur Investment where he founded a quantitative trading desk and ran the domestic derivatives desk. Dr. Sigurjonsson has broad experience in developing statistical models and algorithms for critical real-world applications. He received his C.S. in Electrical and Computer Engineering from the University of Iceland, M.S. and Ph.D. in Electrical Engineering from Stanford University. At Stanford University he was a member of the Information Theory Group where he conducted research in the areas of estimation, information theory and probability.
Asim Siddiqui, PhD
Vice President, Product Development
Dr. Siddiqui has over 15 years in system engineering and bioinformatics. Most recently, he served as Director of Bioinformatics at Life Technologies. For his work there on bioinformatics methods and software for next generation sequencing, Dr Siddiqui was awarded a Life Technology Inventor Award. Prior to this, Dr. Siddiqui managed his own consulting firm and served as Vice President of Research for Sirius Genomics, both in Vancouver, BC. He spent several years at the Genome Sciences Centre (GSC), part of the BC Cancer Agency, as Bioinformatics Group Leader where he was part of many collaborative projects (including the rat and poplar genomes). While at GSC, Dr Siddiqui led the creation of an international public-private consortium to define standards for NGS data. He holds 6 provisional patents, and has been author or co-author of over 30 peer-reviewed publications. Dr. Siddiqui holds a PhD in Bioinformatics from Oxford University (UK), and an undergraduate in Physics with honors from Cambridge University (UK).
Vice President of Commercial Operations
Mr. Chapman began his career in the Department of Human Genetics at UCLA. While at UCLA, he contributed to the selection process and design of oligonucleotide arrays used to identify SNPs associated with Multiple Sclerosis. As a result of his work, he was selected to work on an NIH project in Finland. After leaving UCLA, Mr. Chapman worked in a commercial role with Genzyme Genetics, where his team was responsible for prenatal and preconception genetic testing revenues nearing $100 million. During his time at Genzyme, Mr. Chapman’s efforts reshaped the way medicine is practiced. Mr. Chapman led Genzyme’s sales initiative into population screening for Fragile X Syndrome. He established the largest global network of physicians who routinely screen for the disorder, and he radically altered the way the test is offered to pregnant and preconception patients. In 2005, Mr. Chapman proved to be a visionary when he elevated carrier screening for Spinal Muscular Atrophy (SMA) to the forefront of business development efforts at Genzyme. Later, he played a critical role in the groundbreaking launch of SMA carrier screening. These efforts again reshaped the way medicine is practiced. Today, SMA screening is recommended by the ACMG and is routinely offered to couples across the United States. At Genzyme, Mr. Chapman was the direct recipient of 27 sales awards and was, most notably, a two-time winner of the prestigious Alpine Award, which recognizes outstanding achievement and innovation. The award is annually given to only one person throughout Genzyme Corporation, which has over 8,000 employees worldwide, with the recipient personally selected by CEO Henri Teermer. Since joining Natera in 2010, Mr. Chapman has been responsible for building Natera’s sales and managed-care teams and more recently has taken a broader role leading the broader commercial team. During his tenure at Natera, Mr. Chapman has overseen the successful launch of five products and the establishment of the premier worldwide distribution network for noninvasive prenatal testing. Steve graduated with honors and holds a B.Sc. in Microbiology, Immunology, and Molecular Genetics from University of California, Los Angeles.
Solomon Moshkevich, MBA
Vice President of Marketing and Business Development
Mr. Moshkevich is passionate about improving patient outcomes and lowering healthcare costs through non-invasive technologies and innovative reimbursement models. He began his career as a consultant with Bain & Company in New York, then moved on to join the investment team of Parthenon Capital Partners in Boston. More recently, he led a regional growth strategy for SABMiller across Russia that resulted in significant market share growth. With the Disease Management product team of OptumHealth (a UnitedHealth Group company), Mr. Moshkevich was the first to identify and measure the value of provider engagement in Optum’s disease management services, leading to lower costs and improved patient outcomes. And as a member of the start-up team at Organ-i, he developed a value story and commercialization strategy for a non-invasive genetic test that diagnoses acute rejection of solid organ transplants. Since joining Natera in 2011, he has been responsible for the establishment of its international business, now active across more than 25 countries worldwide, and the development of key channel partnerships in the US. Mr. Moshkevich holds a B.A. summa cum laude in Mathematics and Economics from Columbia University, and an M.B.A. from the Stanford University Graduate School of Business.
Barbara Pettersen, MS, CGC
Ms. Pettersen is a board certified genetic counselor who has worked in the field of clinical genetics for over 30 years and has extensive experience in preimplantation, prenatal, pediatric and adult genetics along with specific expertise in the clinical applications of genetic testing. Prior to joining Natera in 2007, Ms. Pettersen has held genetic counseling positions at the University of Colorado Health Sciences Center; Stanford University Medical Center; and Kaiser-Permanente as Clinical Consultant to the Molecular Laboratory; as well as founding her own private practice. She served on the board of the National Society of Genetic Counselors for two terms, was the recipient of the NSGC Regional Leadership award, and has served as board member for the American Board of Genetic Counselors and Chair of the ABGC Certification Examination Committee. She is also a member of the American College of Medical Genetics, the American College of Obstetrics and Gynecology and the American Society of Reproductive Medicine. Ms. Pettersen holds a B.A. in psychology and M.S. degree in Medical Genetics from the University of Wisconsin-Madison. She has co-authored publications on topics ranging from preimplantation genetic diagnosis for aneuploidy, chromosome rearrangements and single gene disorders, and genetic testing for recurrent miscarriages, cystic fibrosis, fragile X syndrome, inherited cancer syndromes, and expanded newborn screening.
Daniel Rabinowitz, LL.M.
Mr. Rabinowitz currently serves as General Counsel and Corporate Secretary of Natera. Prior to joining Natera he was a corporate partner at the law firm McDermott, Will & Emery, and before that, was a corporate lawyer at the law firm Davis Polk & Wardwell. During this time Mr. Rabinowitz worked in the United States and Europe advising domestic and foreign, as well as public and private, companies on capital raisings, M&A, investment management and compliance with US federal and state securities law. He then studied genetics, biochemistry, and molecular biology at the Harvard University Extension School and attended courses on the legal and ethical aspects of biotechnology at Harvard Law School. Mr. Rabinowitz completed his B.A. and LL.B. degrees at the University of the Witwatersrand, South Africa, graduating at the top of his law school class, and completed his LL.M. at New York University School of Law on Rotary Foundation and Fulbright Scholarships.